AstraZeneca Confirms Exploring Potential Strategic Options With Acerta Pharma
Further to recent speculation, AstraZeneca (NYSE: AZN) confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.
The Company will make a further announcement if and when appropriate.
Dow Jones first reported a potential deal between the companies on Friday.
AstraZeneca shares closed down $0.22 on Friday, at $33.25.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.